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ABSTRACT
Interferon-gamma (IFN-γ) release assays have improved latent tuberculosis (TB) detection 
and have been considered promising for the diagnosis of TB disease. However, diagnosis 
efficacy data is limited in high burden countries. The aim of this study was to determine 
the diagnostic potential of the QuantiFERON-TB Gold In-Tube (QFT-GIT) test for the 
diagnosis of active TB in an endemic setting for TB. A cross-sectional study was conducted 
in a group of 102 Thai patients with clinical symptoms and chest x-ray findings suggesting 
of active pulmonary TB and a group of 112 healthy adults. Testing was carried out using 
sputum microscopy, mycobacterial culture and QFT-GIT test. Of these patients, QFT-GIT 
was positive in 73 (71.57%), negative in 27 (26.47%), and undetermined in 2 (1.96%) cases. 
Among healthy controls, QFT-GIT was positive in 18 (16.07%), negative in 93 (83.04%), 
and undetermined in 1 (0.89%) person. Based on TB culture results, the sensitivity of QFT-
GIT for diagnosing active TB was 84.21% (95% confidence interval (CI); 72.13-92.52). The 
positive and negative predictive values were 65.75% (95% CI; 59.26-71.70) and 66.67% (95% 
CI; 49.94-80.04), respectively. The median IFN-γ level in culture-confirmed TB patients was 
3.91 compared to 0.03 IU/mL of the healthy group. QFT-GIT appears to be a useful indirect 
test for TB diagnosis in Thailand and its use is recommended in association with clinical 
and radiological assessments for identifying active or latent TB. 
KEYWORDS: Active tuberculosis. Latent tuberculosis. Diagnosis. QuantiFERON. 
Interferon-gamma release assay. IGRA
INTRODUCTION
Tuberculosis (TB) remains a major global health threat. Despite significant 
efforts to control the disease, mortality and incidence rates remain extremely high1. 
An essential factor to control the spread of TB is the ability to diagnose the disease at 
the early stages. Smear microscopy is generally available but it has poor sensitivity. 
At least, 5,000 bacilli per mL of sputum are required for a smear-positive result. 
In addition, a positive finding is not specific only to Mycobacterium tuberculosis. 
On the other hand, mycobacterial culture, the gold standard, usually takes several 
weeks until final results. It also requires specific laboratory equipment, technicians 
with additional skills and appropriate bio-safety conditions2. Therefore, sensitive 
tools complementing conventional tests are needed to guide the initiation of therapy 
when the diagnosis of TB disease remains doubtful.
Interferon-gamma release assays (IGRAs) are immunodiagnostics tools in 
which interferon-gamma (IFN-γ) released by T-cells in response to Mycobacterium 
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tuberculosis-specific antigen is measured3. During the 
past decade, two commercial in vitro IGRAs, including 
the QuantiFERON-TB Gold In-Tube (QFT-GIT) test 
(Cellestis, Ltd., Victoria, Australia) and T-SPOT.TB (Oxford 
Immunotec, UK), have been introduced for the early detection 
of M. tuberculosis infection. The QFT-GIT test detects IFN-γ 
production after the stimulation of whole blood samples with 
specific M. tuberculosis antigens, Early Secretory Antigenic 
Target-6 (ESAT-6), Culture Filtrate Protein-10 (CFP-10) and 
TB7.7 (Rv2654). These antigens are absent from all Bacille 
Calmette-Guérin (BCG) strains, as well as most common 
non-tuberculous mycobacteria. The QFT-GIT has been 
reported to have higher sensitivity, specificity and be more 
attractive than the tuberculin skin test (TST) which may result 
in interpretation errors, including the need of two clinic visits. 
However, the QFT-GIT performance in detecting active or 
latent tuberculosis infection (LTBI) can vary depending on 
the tested populations and regions4.
The QFT-GIT test has been largely employed to 
evaluate the diagnosis of M. tuberculosis infection in 
developed countries4. In recent years, the studies of 
QFT-GIT performance have become more documented 
in non-developed countries such as Iran, India, Zambia, 
Brazil, etc.5,6. Currently available data suggest that the 
QFT-GIT test is less influenced by prior BCG vaccination 
and environmental mycobacteria7. Therefore, the QFT-GIT 
test has been increasingly used in locations where the 
coverage of BCG vaccination is high. Numerous studies 
have assessed the utility of this test in diagnosing latent 
TB infection (LTBI) in various clinical settings8. Regarding 
active TB, the use of IGRAs has been unclear particularly 
in high prevalence settings. Although the limitations of 
QFT-GIT in diagnosing TB disease have been recognized, 
it continues to be recommended by some investigators and 
used to aid in the diagnosis of tuberculosis9,10. Thailand 
is a TB-endemic country with an estimated prevalence of 
172 per 100,000 inhabitants1. National guidelines have 
not yet been established using IGRA for LTBI screening 
or the diagnosis of TB, while the TST is the test of choice 
for identifying TB infection. Currently, the QFT-GIT test 
is available and has been used for the diagnosis of LTBI in 
Thailand. Nevertheless, it has been used in clinical practice 
for the rapid confirmation of TB disease or for ruling out 
active TB in many suspicious cases, especially when there 
are insufficient or non-sputum samples. Collecting blood 
samples may not frequently encounter difficulties compared 
with other specimens collection and QFT-GIT can provide 
rapid results, within two days. Despite the high cost, 
QFT-GIT may be a useful additional test for TB diagnosis 
especially when reference test results are not available. 
However, data on the utility and the efficacy of QFT-GIT 
for diagnosing active TB are limited in this setting. Here, 
we assessed the diagnostic potential of the QFT-GIT assay 
for detecting TB infection among the active TB patients in 
Thailand, with healthy adults as the controls.
MATERIALS AND METHODS
Study subjects
This study was reviewed and approved by the Ethics 
Committee of the Ministry of Public Health, Thailand and 
was conducted from September 2013 through October 
2015. The participants were clinically diagnosed with 
pulmonary tuberculosis (PTB) and there was a group of 
healthy subjects. Informed consent was obtained from 
all participants before the enrollment in this study. Data 
concerning primary demographic characteristics and 
sputum smear results were collected.
Eligible patients included presumptive active TB cases 
(PTB) with sputum smear positive or negative and aged 
over 15 years. The presence of active TB was defined as 
the presence of abnormal images suggestive of TB in the 
chest x-ray or clinical manifestations such as a persistent 
cough for more than two weeks, night sweats, prolonged 
fever, weight loss or hemoptysis, with or without a history 
of TB exposure. As the disease could not be confirmed 
by bacteriological culture at the time of recruitment, the 
physicians determined whether the patients suffered from 
TB based on clinical, microbiological and radiological 
findings. For patients considered as suspected cases of PTB, 
if the sputum culture was positive they were diagnosed as 
certain TB patients. Subjects were recruited to this study 
consecutively. To avoid misinterpretation due to an immune 
response modulation, any patient who had previously 
received anti-tuberculous treatment, steroids, anti-TNF 
compounds or any other medication that might reduce the 
cellular immunity was excluded from the study. Patients 
with self-reported disease or presenting symptoms of 
diseases that compromise the immune system such as HIV, 
diabetes or cancer were not eligible. Clinical examination 
and screening for other underlying diseases were performed 
following routine guidelines. 
The healthy subject group included adults in good 
physical conditions aged over 15 years, with no apparent 
TB symptoms, abnormal chest X-ray findings, history of 
TB or exposure to the disease. Their contact with physicians 
consisted primarily of annual medical check-ups.
Specimen collection and mycobacteriology
As part of a routine procedure for TB diagnosis, three 
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sputum samples, the first sputum, second early morning and 
the third sputum were collected from the patients, with all 
subjects taken for radiological examination. The collected 
sputum specimens were stained for acid-fast bacilli (AFB) 
microscopy by Ziehl-Neelsen method, and decontaminated 
samples were cultured in Lowenstein-Jensen (LJ), a 
conventional medium for the isolation and identification 
of M. tuberculosis11. Blood samples were drawn from all 
recruited study subjects for QFT-GIT at the time of standard 
microscopic examination, after which the QFT-GIT assay 
was carried out.
QFT-GIT assay
The whole-blood assay of QFT-GIT was performed 
according to the manufacturer’s instructions (Cellestis, Ltd., 
Victoria, Australia). Briefly, a total of 3 mL of peripheral 
venous blood was taken from each subject and immediately 
transferred to 3 QFT-GIT tubes of 1 mL each (Nil control-
no antigen for negative control, phytohaemagglutinin or 
mitogen for positive control and TB-specific antigens). 
Then, the tubes were homogenized by inversion for 
ten times and were subsequently incubated for 16-24 h 
(targeting 16-18 h incubation time in our study) at 37 °C. 
Plasma samples were recovered after centrifugation and 
stored at 4 °C until assayed. QFT-GIT enzyme-linked 
immunosorbent assay (ELISA) was carried out to measure 
IFN-γ within 2 weeks after blood collection. Raw optical 
densities were interpreted using specific software supplied 
by the manufacturer (QuantiFERON-TB Gold analysis 
software version 2.50.4). The results obtained by the Nil 
control were subtracted from the mitogen control and 
the antigen-stimulated samples. The cut-off point for 
the diagnosis was set according to the manufacturer’s 
instructions. In brief, if the IFN-γ secretion in response 
to TB antigens after subtracting Nil control IFN-γ was 
0.35 IU/mL, it was considered positive. If the value was 
less than 0.35 IU/mL, it was considered negative. The 
result of the test was considered undetermined if an 
antigen-stimulated sample was negative and the value of 
the positive control was less than 0.5 IU/mL. Subjects with 
IFN-γ secretion over 8.0 IU/mL in the Nil control samples 
were also considered undetermined for QFT-GIT.
Statistical analysis
Numbers, frequencies, percentages and medians were 
used to present data. The association between QFT-GIT 
results of the two groups was determined by the Chi-square 
test or the Fisher’s exact test using SAS® University Edition. 
A p-value less than 0.05 was considered a statistically 
significant difference. The diagnostic performance of the 
QFT-GIT test was assessed using sensitivity and positive/
negative predictive values. Sensitivity was calculated 
without undetermined results.
RESULTS
Demographic and microbiological characteristics of 
study subjects
A total of 214 subjects were enrolled in the study. Of 
these participants, 112 were healthy adults and 102 were 
new clinically diagnosed PTB patients. The demographic 
profile of TB patients and healthy controls is shown in 
Table 1. Patients and healthy controls had a median age of 
37 (range, 15-68 years) and 42 (range, 15-76), respectively, 
and they were not age-matched. Sixty-nine of 102 (67.65%) 
patients and 76 of 112 (67.86%) healthy adults were men. 
Sputum smear microscopy was positive in 53 of 102 
(51.96%) patients, while smear was negative in 49 of 102 
(48.04%). Culture for M. tuberculosis was positive in 59 
of 102, therefore, the culture positive rate in this study was 
57.84%. Based on culture confirmation for M. tuberculosis, 
TB cases were definitively identified in a total of 59 cases, 
of which 48 and 11 were AFB smear positive and negative, 
respectively (Table 2).









Female 33 (32.35) 36 (32.14)
Male 69 (67.65) 76 (67.86)
Age (min-max), median (15-68), 37 (15-76),42
15-25 19 (18.63) 20 (17.86)
26-35 30 (29.41) 23 (20.54)
36-45 21 (20.59) 32 (28.57)
46-60 27 (26.47) 29 (25.89)
61-76 4 (3.92) 8 (7.14)
Unknown 1 (0.98) -
Sputum smear status
Smear positive 53 (51.96) -
Smear negative 49 (48.04) -
MTB Culture status
Culture positive 59 (57.84) -
Culture negative 43 (42.16) -
PTB, pulmonary tuberculosis; MTB, Mycobacterium tuberculosis
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Performance of QFT-GIT for TB diagnosis
Overall, 73 (71.57%), 27 (26.47%) and 2 (1.96%) of the 
cases had positive, negative and undetermined QFT-GIT 
results, respectively compared with 18 (16.07%), 93 (83.04%) 
and 1 (0.89%) of the controls respectively, with p-values 
< 0.0001 for positive and negative results. In subgroup 
analysis, the positive rate of QFT-GIT for the diagnosis of 
active PTB in the group of smear-positive and culture-positive 
cases was 40 of 48 (83.33%). The positive rate for QFT-GIT 
in detecting smear-negative and culture-positive PTB patients 
was 8 of 11 or 72.73%. In culture-negative patients, positive 
QFT-GIT was 60% and 57.89% in the group of AFB positive 
and negative, respectively. The number of positive results 
for each group of PTB patients obtained by the IFN-γ assay 
is shown in Table 2. The difference(s) in the percentages 
of QFT-GIT results for the IFN-γ test in each group of 
patients compared with those of the controls were significant 
(p-values < 0.05). A undetermined or uninterpretable result 
was found among the group of active PTB patients in two 
cases due to the low immune response to mitogen antigen 
in a positive control tube. Of the 112 healthy subjects, 18 
(16.07%) had an IFN-γ level over 0.35 IU/mL, indicating 
probable M. tuberculosis infection or LTBI. One healthy 
adult had an IFN-γ level over 0.35 IU/mL, but less than 
25% of the Nil value. The interpretation of this result was 
QFT-GIT negative. A undetermined result caused by the low 
immune response was also found in only one subject among 
the healthy controls (0.89%). Retesting of these samples 
has not been performed and all three undetermined results 
were excluded from further analysis. There was a significant 
difference of positive QFT-GIT results between the TB 
patient group and the asymptomatic or non-TB, healthy 
group, p-value <0.05. The sensitivity and predictive values 
for the diagnosis of active TB were calculated by excluding 
two culture positive cases presenting undetermined results 
for QFT-GIT. Among the remaining 57 culture-positive 
patients, 48 had a QFT-GIT positive result. Therefore, the 
sensitivity of QFT-GIT in culture-confirmed TB cases was 
84.21% (95% CI; 72.13-92.52), whereas the sensitivity 
in the patient group with AFB smear-positive, regardless 
of the culture result, was 84.31% (95% CI; 71.41-92.98) 
(Table 3). Further analysis based on clinical symptoms, the 
smear microscopy result and radiological evaluation indicated 
that the sensitivity of QFT-GIT for the detection of active 
TB disease was 73.0% (95% CI 63.20-81.39). The positive 
predictive values (PPV) and the negative predictive value 
(NPV) are detailed in Table 3.
Level of IFN-γ between patient and control groups
The levels of IFN-γ in response to TB specific antigens in 
PTB patients and healthy adults are shown in Figure 1. There 
was an overlapping of IFN-γ levels between the groups of 
active TB disease and asymptomatic infected or LTBI. Four 
of LTBI showed very high levels of IFN-γ, over 10.0 IU/mL, 
thus the level of IFN-γ cannot be used alone to distinguish 
active from latent TB. Apparently, the analysis of IFN-γ 
levels in PTB patients revealed that most active TB cases 
(83.56%) in this study were positive to QFT-GIT with IFN-γ 
levels over 1.0 IU/mL. In culture confirmed PTB, the median 
IFN-γ level was 3.91 compared to 0.03 IU/mL of the healthy 
group. Among the healthy group, the median IFN-γ levels in 
LTBI and in non-LTBI were 1.44 IU/mL, and 0.02 IU/mL, 
respectively. The median IFN-γ levels in patients with smear 
positive and culture positive (S+C+), smear positive and 
culture negative (S+C-), smear negative and culture positive 
(S-C+), including smear negative and culture negative (S-C-), 
were 3.24, 0.52, 4.67, 0.71 IU/mL, respectively. 
DISCUSSION
The measurement of IFN-γ in antigen-stimulated blood 
samples by QFT-GIT has been proposed as an in vitro 
Table 2 - QuantiFERON-TB Gold In-Tube (QFT-GIT) results in PTB patients and healthy subjects 
Subjects Number of subjects Positive (%) Negative (%) Indeterminate (%) p-valuea
Suspected PTB 102 73(71.57) 27 (26.47) 2 (1.96) <0.0001
S+, C+ 48 40 (83.33) 6 (12.5) 2 (4.17) <0.0001
S+, C- 5 3 (60.0) 2 (40.0) - 0.04b
S-, C+ 11 8 (72.73) 3 (27.27) - 0.0002b
S-, C- 38 22 (57.89) 16 (42.11) - <0.0001
Healthy adults 112 18 (16.07) 93 (83.04) 1 (0.89)
aQFT-GIT results in patients clinically diagnosed having PTB compared to those of healthy controls using Chi-square or Fisher’s 
exactb test. PTB, pulmonary tuberculosis; S, acid-fast bacilli smear result; C, culture result. The patient group was stratified based 
on results of sputum microscopy and mycobacterial culture
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alternative method for latent TB diagnosis and has the 
potential to provide rapid and reliable results to diagnose 
active TB12-14. There are several published reports on the 
performance of the QFT-GIT test for TB diagnosis used 
in non-endemic countries15 but few studies have been 
carried out in TB or TB-HIV endemic settings16. This study 
reported the use of the QFT-GIT assay in Thailand, where 
the burden of TB is high and BCG vaccination is commonly 
employed. In this study, the positive rate of QFT-GIT was 
84.21% in culture-positive cases and 84.31% in AFB smear-
Table 3 - Diagnostic performance of the QuantiFERON-TB Gold In-Tube (QFT-GIT) test in active tuberculosis patients compared 
with microbiological results and clinical TB diagnosis












Number of subjects (102b) AFB smear
Positive Negative
QFT-GIT






Number of subjects (214c) Clinical Dx TB
Suspected Healthy
QFT-GIT






a2 from MTB culture positive were indeterminate by QFT-GIT; b2 from AFB smear positive were indeterminate by QFT-GIT; c2 from 
suspected tuberculosis cases and one from healthy adults were indeterminate by QFT-GIT. MTB, Mycobacterium tuberculosis; CI, 
confidential interval; PPD, positive predictive value; NPV, negative predictive value; AFB, acid-fast bacilli; Dx, diagnosis
Figure 1 - Quantitative responses of the QuantiFERON-TB Gold In-Tube test in pulmonary tuberculosis patients in relation to 
acid-fast bacilli smear and culture results compared with the responses of healthy adults. Individual QFT-GIT results are plotted 
according to their diagnosis. The cut-off value for positive QFT-GIT is represented by the dotted line (0.35 IU/mL)
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positive group, which was in the range described in some 
previous reports17-20. Previously published studies have 
also demonstrated the very high specificity of QFT-GIT, 
giving no reason to doubt the validity of QFT-GIT results 
for detecting MTB infection21,22. The high background of 
LTBI may result in poor specificity for active tuberculosis 
diagnosis in high-burden countries. In this study, we 
reported the percentage of LTBI to be 16.07%. It has been 
recommended that QFT-GIT could be used to rule out the 
suspicion of active TB disease among clinically suspected 
subjects23. In this condition, those suspected of having TB 
would show low levels of IFN-γ (< 0.35 IU/mL). It was 
proposed that QFT-GIT could be used as a confirmatory 
test for active TB disease at the moment of the clinical 
diagnosis, before culture results are available17. QFT-GIT is 
less influenced by prior BCG vaccination and environmental 
mycobacteria3,7. Therefore, high rates of BCG vaccination 
should not be a concern of use in this setting and elsewhere. 
QFT-GIT has considerably high sensitivity, comparable 
with or superior to that of TST. In addition, the sensitivity of 
QFT-GIT has been reported to be higher for detecting active 
TB disease in low endemic countries24-26. The positive rate 
of QFT-GIT in detecting active TB in Thailand reported in 
this study appeared to be similar to those of other countries. 
The slight differences in sensitivity found by our study and 
others may be explained by the difference in the number 
of analyzed patients and their individual characteristics. 
The false-negative results of QFT-GIT in active TB have 
been described previously27-29. Some hypotheses have 
been raised to explain the negative results in active TB 
patients. Immunocompromised patients with active TB 
at the beginning of the treatment were also reported and 
they were more likely to have negative QFT-GIT results. 
In immunocompetent patients with active TB but negative 
QFT-GIT, the explanation for this finding involves the 
release of anti-inflammatory cytokines by peripheral blood 
mononuclear cells and a temporary depression of the T-cell 
response. HIV is one of the major influencing factors for 
QFT-GIT diagnostic results30. Diabetes mellitus is another 
factor affecting the expression of Th1-related cytokines31. 
In addition, it was reported that QFT-GIT response could be 
diminished in cases of advanced TB32. Therefore, negative 
QFT-GIT test results should not be used alone to exclude 
active TB. For LTBI, as QFT-GIT is recommended for 
LTBI detection, a prevalence of LTBI should be further 
investigated and considered for appropriate management 
in endemic countries.
The limitations of this study included the small sample 
size, the lack of sociodemographic data, no molecular results 
to rapidly confirm the clinical diagnosis of tuberculosis and 
the absence of clinical information regarding the routine 
screening of other underlying diseases, as well as of the HIV 
status of study patients. We noted that the culture sensitivity 
in the present study was as low as 57.8%. The sensitivity 
of mycobacterial cultures can vary from 20-100%33 and in 
a similar study, the sensitivity of MTB sputum culture was 
60%34. Therefore, the culture sensitivity in our study was 
not out of this range. Another point that worths discussion is 
the role of culture as the gold standard, as it may sometimes 
result in false negative results due to poor sputum sample 
collection or paucibacillary sputum samples. Although the 
study had some limitations, the results demonstrated the 
usefulness of QFT-GIT when used in TB high-prevalence 
settings for diagnosis of M. tuberculosis infections. It is 
more useful in the case of smear-negative PTB patients 
and can help to rule out active pulmonary TB suspicions. 
Nevertheless, the QFT-GIT  assay can result in false 
negative or undetermined results in active TB with low 
T-lymphocytes response. Therefore, QFT-GIT  should 
not be used alone or as the final test for the identification 
of active TB patients. Culture results are still required for 
conclusive TB diagnosis. We have also shown that QFT-GIT 
could not discriminate active TB disease from latent TB 
infection alone. Undetermined results were found in a 
small number of patients in this study. It was reported that 
QFT-GIT undetermined results increase with age and are 
associated with the severity of other underlying diseases 
in patients with active TB disease. Because of the small 
number of elderly patients, the study had insufficient data 
to address this issue. For further studies, the testing in 
environmental mycobacteriosis and in HIV-infected patients 
in Thailand is proposed.
CONCLUSIONS
In general, there is concern about the usefulness of 
QFT-GIT for active TB diagnosis in TB-endemic countries. 
Based on our results, we conclude that QFT-GIT is useful 
as a complementary test for diagnosing active TB cases. It 
appeared to be useful for detecting latent tuberculosis in a 
high prevalence setting country as Thailand. IFN-γ levels 
could not distinguish between active and latent TB infection. 
Therefore, QFT-GIT cannot be used separately without 
considering clinical and radiological data for identifying 
active or latent TB. There is still much to learn on the QFT-
IT assay and its performance in different clinical settings, 
meaning that the subject deserves further study.
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